|
KMID : 1103920080140010046
|
|
Korean Journal of Hepatology
2008 Volume.14 No. 1 p.46 ~ p.57
|
|
|
Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis C
|
|
Lee Hyun-Ju
Eun Jong-Ryul
Choi Jae-Won
Kim Kyeong-Ok
Moon Hee-Jung
|
|
|
Abstract
|
|
|
Background : This study compared the efficacy and safety of combined peginterferon alfa (PEG-IFN) and ribavirin with that of combined interferon alpha (IFN-α) and ribavirin, according to the treatment duration in Korean patients with chronic hepatitis C.
Methods : Medical records of 86 patients treated with PEG-IFN and ribavirin (mean age, 50.7 years; males/females, 57/29; genotypes 1/2, 59/27) and 134 patients treated with IFN-α and ribavirin (mean age, 50.9 years; males/females 74/60; genotypes 1/2, 79/55) were reviewed. Ribavirin was administered at doses of 600-1,200 mg and 600-800 mg in patients with genotypes 1 and 2, respectively.
Results : Sustained virological responses (SVRs) were evident in 68.4% and 41.7% of genotype 1 patients treated for 48 weeks in the PEG-IFN and IFN-α groups, respectively (P=0.021), and in 94.1% and 64.9% of genotype 2 patients treated for 24 weeks (P=0.026). Some genotype 1 patients treated for 24 weeks in the PEG-IFN group, who all exhibited negative HCV PCR results at week 12, showed an SVR of 87.5% (7/8).
Conclusion : The rate of SVRs in Korean patients with chronic hepatitis C was higher for combined PEG-IFN and ribavirin than for combined IFN-α and ribavirin. Further study is needed to clarify the outcome of short-term therapy in patients with a rapid or early virological response. (Korean J Hepatol 2008;14:46- 57)
|
|
|
KEYWORD
|
|
|
Peginterferon alfa, Interferon alfa, Hepatitis C, Sustained virological response, Treatment duration
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|